Dynavax Technologies
Biotechnology Research • Emeryville, California, United States
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on …
Reported headcount
327
Headcount reported in the resolved company record. It is independent of the number of profiles indexed by Super Carl.
Company record. Source date unavailable.
Observed active job postings
0
Active postings in the available job data. Postings may be duplicated or stale and are not a verified count of vacancies or hires.
Indexed job postings. Source date unavailable.
Reported annual revenue estimate
$330.5M
Annual revenue from the resolved company record; estimates may differ from filed accounts.
Company record. Source date unavailable. Estimate.
Reported total funding
$1.7B
Reported cumulative funding in the available company record; missing value does not mean no funding.
Company record. Source date unavailable.
Reported latest funding round
$225M
Reported amount of the latest funding round available in the company record.
Company record. Source date unavailable.
Calculated as of 2026-10-25. Source records may be older.